Important Update for Temporary Facilitated Access Mechanism for Rheumatology and Changes to OHIP+
There is an important update on the Temporary Facilitated Access (TFA) mechanism for rheumatology, regarding the imminent changes on March 31, 2019. The ORA has been asked to pass along the attached letter […]
Ontario eConsult Service
The Ontario Rheumatology Association is working on improving patient access to specialist rheumatologic care across the province. One of the ways that this could be improved is enhanced access to subspecialist rheumatologists for […]
Drug Shortage Update – Methotrexate
There is a drug shortage update for Methotrexate. More information is available via this link: Drug Shortage MTX […]
Ondansetron for Methotrexate-Induced Nausea/Vomiting
The ORA EAP Committee met with the MOHLTC last year and submitted a request to have ondansetron funded for pediatric patients with rheumatic diseases who are receiving weekly oral or subcutaneous methotrexate. It […]
Updated Notice – Temporary Facilitated Access Mechanism
Please find the attached notice from the Executive Officer regarding an update to pharmacies about the claims submission process under the Temporary Facilitated Access Mechanism (TFA Rheumatology) using the Health Network System (HNS). […]
Health Canada and Biosimilar Drugs – Important Information for Healthcare Professionals
The following notice was received by the ORA from Health Canada on December 3, 2018: Health Canada’s Biologics and Genetic Therapies Directorate is asking healthcare professionals who prescribe, dispense or administer biologic drugs […]
Opportunity for Arthritis Health Professionals!
Do you know ou know or work with health professionals who want to stay current withevidence-based knowledge in the field of rheumatology and arthritis care? Please share this important information: AHPA Opportunities […]
A New Quality Standard is Now Available for Osteoarthritis
For further information, please visit this link: New Quality Standard – Osteoarthritis […]
Concerned About the CPSO Draft Policy Titled “Continuity of Care?”
The following link will take you to the members’ only section of our website. Here you will find instructions on how to share your concerns about the CPSO draft policy. You will be […]
New Infliximab Biosimilar (Renflexis) Approved by ODB With LU code Criteria
To review the update from the MOHLTC, please visit this link: Renflexis FAQs. The updated ORA EAP Forms are available via this link: ORA EAP Forms. […]
